Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from mycobacterium tuberculosis

Biochemistry

Volumn 53, Issue 22, 2014, Pages 3671-3678

  Hazra, Saugata ^a   Xu, Hua ^a   Blanchard, John S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; MASS SPECTROMETRY; SEWAGE TREATMENT PLANTS;

ACYL-ENZYME COMPLEX; CARBAPENEM ANTIBIOTIC; CHROMOGENIC SUBSTRATE; CLEAVAGE PRODUCTS; FT-ICR MASS SPECTROMETRY; HIGH RESOLUTION CRYSTAL STRUCTURE; MICROMOLAR CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS;

ENZYMES;

BETA LACTAMASE; DORIPENEM; ERTAPENEM; MEROPENEM; TEBIPENEM;

ACYLATION; ACYLATION AND DEACYLATION; ARTICLE; CHEMICAL COMPOSITION; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DEACYLATION; DRUG CONFORMATION; DRUG HYDROLYSIS; DRUG STRUCTURE; ENZYME INHIBITION; HYDROGEN BOND; ISOMERIZATION; MASS SPECTROMETRY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RING OPENING; STEREOCHEMISTRY;

BETA-LACTAMASES; CARBAPENEMS; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; MYCOBACTERIUM TUBERCULOSIS; SUBSTRATE SPECIFICITY;

EID: 84902160791     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi500339j     Document Type: Article

References (31)

1. (2007) Robbins Basic Pathology, 8 th ed. (Kumar, V., Abbas, A. K., Fausto, N., and Mitchell, R. N., Eds.) pp 516-522, Saunders Elsevier, Philadelphia, PA.
2. Konstantinos, A. (2010) Testing for tuberculosis Australian Prescriber 33, 12-18
3. (2011) The sixteenth global report on tuberculosis, World Health Organization, Geneva, Switzerland, http://www.who.int/tb/publications/global- report/2011/gtbr11-full.pdf.
4. (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response, World Health Organization, Geneva, Switzerland, http://whqlibdoc.who.int/publications/2010/9789241599191-eng.pdf.
5. Netto, E. M., Dye, C., and Raviglione, M. C. (1999) Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. Global Monitoring and Surveillance Project Int. J. Tuberc. Lung Dis. 3, 310-320
6. Fact sheet: a global perspective on tuberculosis, CDC, Atlanta, GA, http://www.cdc.gov/tb/publications/factsheets/default.htm.
7. Barry, C. E., 3rd and Blanchard, J. S. (2010) Chemical biology of new drugs in development for tuberculosis Curr. Opin. Chem. Biol. 14, 456-466
8. Goffin, C. and Ghuysen, J. M. (1998) Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs Microbiol Mol. Biol. Rev. 62, 1079-1093
9. Holten, K. B. and Onusko, E. M. (2000) Appropriate prescribing of oral beta-lactam antibiotics Am. Fam. Physician 62, 611-620
10. Neu, H. C. (1969) Effect of beta-lactamase location in Escherichia coli on penicillin synergy Appl. Microbiol. 17, 783-786
11. Flores, A. R., Parsons, L. M., and Pavelka, M. S., Jr. (2005) Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to β-lactam antibiotics Microbiology 151, 521-532
12. Hall, B. G. and Barlow, M. (2005) Revised Ambler classification of β-lactamases J. Antimicrob. Chemother. 55, 1050-1051
13. Fisher, J. F., Meroueh, S. O., and Mobashery, S. (2005) Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity Chem. Rev. 105, 395-424
14. Xu, H., Hazra, S., and Blanchard, J. S. (2012) NXL104 irreversibly inhibits the β-lactamase from Mycobacterium tuberculosis Biochemistry 51, 4551-4557
15. Hugonnet, J. E. and Blanchard, J. S. (2007) Irreversible inhibition of the Mycobacterium tuberculosis β-lactamase by clavulanate Biochemistry 46, 11998-12004
16. Hugonnet, J. E., Tremblay, L. W., Boshoff, H. I., Barry, C. E., 3rd, and Blanchard, J. S. (2009) Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis Science 323, 1215-1218
17. Tremblay, L. W., Fan, F., and Blanchard, J. S. (2010) Biochemical and structural characterization of Mycobacterium tuberculosis β-lactamase with the carbapenems ertapenem and doripenem Biochemistry 49, 3766-3773
18. Bassetti, M., Nicolini, L., Esposito, S., Righi, E., and Viscoli, C. (2009) Current status of newer carbapenems Curr. Med. Chem. 16, 564-575
19. Sato, N., Kijima, K., Koresawa, T., Mitomi, N., Morita, J., Suzuki, H., Hayashi, H., Shibasaki, S., Kurosawa, T., and Totsuka, K. (2008) Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia Drug Metab. Pharmacokinet. 23, 434-446
20. Hikida, M., Itahashi, K., Igarashi, A., Shiba, T., and Kitamura, M. (1999) In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity Antimicrob. Agents Chemother. 43, 2010-2016
21. Kato, K., Shirasaka, Y., Kuraoka, E., Kikuchi, A., Iguchi, M., Suzuki, H., Shibasaki, S., Kurosawa, T., and Tamai, I. (2010) Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport Mol. Pharmaceutics 7, 1747-1756
22. Kijima, K., Morita, J., Suzuki, K., Aoki, M., Kato, K., Hayashi, H., Shibasaki, S., and Kurosawa, T. (2009) Pharmacokinetics of tebipenem pivoxil, a novel oral carbapenem antibiotic, in experimental animals Jpn. J. Antibiot. 62, 214-240
23. Tremblay, L. W., Xu, H., and Blanchard, J. S. (2010) Structures of the Michaelis complex (1.2 Å) and the covalent acyl intermediate (2.0 Å) of cefamandole bound to the active site of the Mycobacterium tuberculosis β-lactamase K73A and E166A mutants Biochemistry 49, 9685-9687
24. Otwinowski, Z. and Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 276, 307-326
25. Potterton, E., Briggs, P., Turkenburg, M., and Dodson, E. (2003) A graphical user interface to the CCP4 program suite Acta Crystallogr., Sect. D: Biol. Crystallogr. 59, 1131-1137
26. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 53, 240-255
27. Pannu, N. S., Murshudov, G. N., Dodson, E. J., and Read, R. J. (1998) Incorporation of prior phase information strengthens maximum-likelihood structure refinement Acta Crystallogr., Sect. D: Biol. Crystallogr. 54, 1285-1294
28. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D: Biol. Crystallogr. 66, 213-221
29. Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 60, 2126-2132
30. The PyMOL Molecular Graphics System, version 1.3, Schrödinger, LLC.
31. Payen, M. C., De Wit, S., Martin, C., Segsels, R., Muylle, I., Van Laethem, Y., and Clumeck, N. (2012) Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis Int. J. Tuberc. Lung Dis. 16, 558-560